Which agents are used for homozygous familial hypercholesterolemia (HoFH)?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

Which agents are used for homozygous familial hypercholesterolemia (HoFH)?

This item tests how to manage homozygous familial hypercholesterolemia, where LDL receptor activity is severely impaired and standard therapies often fall short. HoFH requires strategies that either work independently of LDL receptor function or remove LDL from the blood directly. Lomitapide blocks MTTP, reducing production of VLDL and subsequently lowering LDL in a way that does not depend on LDL receptor activity. Mipomersen targets apoB-100 synthesis, cutting the production of apoB-containing lipoproteins and lowering LDL similarly without relying on receptor function. PCSK9 inhibitors can still help in patients with some residual receptor activity by preventing LDL receptor degradation and increasing receptor recycling, though their effectiveness varies with receptor status. LDL apheresis physically removes LDL cholesterol from circulation and is a key option when drug therapy alone doesn’t achieve target levels. In practice, HoFH often requires a combination of these agents and procedures to reach meaningful LDL-C reductions. Ezetimibe alone, bile acid sequestrants, and regimens relying primarily on statins or niacin are typically insufficient in HoFH because their mechanisms depend heavily on functional LDL receptors, which are markedly compromised in this condition.

This item tests how to manage homozygous familial hypercholesterolemia, where LDL receptor activity is severely impaired and standard therapies often fall short. HoFH requires strategies that either work independently of LDL receptor function or remove LDL from the blood directly. Lomitapide blocks MTTP, reducing production of VLDL and subsequently lowering LDL in a way that does not depend on LDL receptor activity. Mipomersen targets apoB-100 synthesis, cutting the production of apoB-containing lipoproteins and lowering LDL similarly without relying on receptor function. PCSK9 inhibitors can still help in patients with some residual receptor activity by preventing LDL receptor degradation and increasing receptor recycling, though their effectiveness varies with receptor status. LDL apheresis physically removes LDL cholesterol from circulation and is a key option when drug therapy alone doesn’t achieve target levels. In practice, HoFH often requires a combination of these agents and procedures to reach meaningful LDL-C reductions. Ezetimibe alone, bile acid sequestrants, and regimens relying primarily on statins or niacin are typically insufficient in HoFH because their mechanisms depend heavily on functional LDL receptors, which are markedly compromised in this condition.

More practice questions